Q-omics provides the consensus-scored SNORA59A profile across patient tissues and cancer cell-line models. SNORA59A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, SNORA59A is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, SNORA59A RNA expression shows 15,713 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KICH, LIHC, and UVM as cancer lineages where SNORA59A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA59A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA59A survival associations across molecular data types. SNORA59A RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA59A RNA expression–survival associations across cancer types. High SNORA59A expression shows unfavorable associations in KICH, STAD, KIRC and LIHC, but favorable associations in BLCA and HNSC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for SNORA59A RNA expression.
This table summarizes SNORA59A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA59A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA59A shows higher tumor expression in LIHC, KICH, THCA, UCEC, BLCA and CHOL. The LIHC box plot shows higher SNORA59A RNA expression in tumor versus normal tissue (log2 FC = +0.885, t-test p < 0.001).
This table shows molecular features associated with SNORA59A in patient tissues and cancer cell lines. In patient samples, SNORA59A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
